KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables (2017 - 2025)

Historic Receivables for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $2.1 billion.

  • Moderna's Receivables fell 2580.88% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 2580.88%. This contributed to the annual value of $757.0 million for FY2024, which is 5392.57% down from last year.
  • Moderna's Receivables amounted to $2.1 billion in Q3 2025, which was down 2580.88% from $321.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Receivables ranged from a high of $3.2 billion in Q4 2021 and a low of $294.0 million during Q2 2023
  • Its 5-year average for Receivables is $1.8 billion, with a median of $2.0 billion in 2021.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 2303110.98% in 2021, then tumbled by 8930.13% in 2023.
  • Quarter analysis of 5 years shows Moderna's Receivables stood at $3.2 billion in 2021, then crashed by 55.18% to $1.4 billion in 2022, then increased by 13.62% to $1.6 billion in 2023, then plummeted by 53.93% to $757.0 million in 2024, then soared by 172.66% to $2.1 billion in 2025.
  • Its last three reported values are $2.1 billion in Q3 2025, $321.0 million for Q2 2025, and $302.0 million during Q1 2025.